PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The effect and safety of intraperitoneal infusion of PD-1 inhibitor is unclear for patients
with peritoneal metastasis of advanced malignant tumors and malignant ascites. It is planned
to determine the safety and efficacy of intraperitoneal infusion of PD-1 inhibitor
combination with PRaG therapy.